Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer

Journal of Surgical Research

Volumn 113, Issue 1, 2003, Pages 88-95

  Fahy, Bridget N ^a   Schlieman, Michael G ^a   Virudachalam, Subbulakshi ^a   Bold, Richard J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BCL 2; NF B; p21WAF1 CIP1; p27KIP1

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; GEMCITABINE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CELL; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; WESTERN BLOTTING;

EID: 0042235056     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-4804(03)00201-4     Document Type: Article

References (44)

1. Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J. 50:2000;7.
2. Williamson R.C. Pancreatic cancer the greatest oncological challenge . Br. Med. J. 296:1988;445.
3. Evans D.B., Abbruzzese J.L., Rich T.A. Cancer of the pancreas. DeVita V.T., Hellman S., Rosenberg S.A. Cancer, Principles and Practice of Oncology. 1997;1054-1087 J. B. Lippincott Co. Philadelphia.
4. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 7:2002;9.
5. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 79:1994;13.
6. Spataro V., Norbury C., Harris A.L. The ubiquitin-proteasome pathway in cancer. Br. J. Cancer. 77:1998;448.
7. Jesenberger V., Jentsch S. Deadly encounter ubiquitin meets apoptosis . Nat. Rev. Mol. Cell. Biol. 3:2002;112.
8. Kudo Y., Takata T., Ogawa I., Kaneda T., Sato S., Takekoshi T., Zhao M., Miyauchi M., Nikai H. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin. Cancer Res. 6:2000;916.
9. Blagosklonny M.V., Wu G.S., Omura S., el-Deiry W.S. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem. Biophys. Res. Commun. 227:1996;564.
10. Hu Y.X., Watanabe H., Li P., Wang Y., Ohtsubo K., Yamaguchi Y., Sawabu N. An immunohistochemical analysis of p27 expression in human pancreatic carcinomas. Pancreas. 21:2000;226.
11. Hashimoto K., Nio Y., Sumi S., Toga T., Omori H., Itakura M., Yano S. Correlation between TGF-beta1 and p21 (WAF1/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas. Pancreas. 22:2001;341.
12. Lu C.D., Morita S., Ishibashi T., Hara H., Isozaki H., Tanigawa N. Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer. 85:1999;1250.
13. Vrana J.A., Kramer L.B., Saunders A.M., Zhang X.F., Dent P., Povirk L.F., Grant S. Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells relationship to apoptosis and differentiation . Biochem. Pharmacol. 58:1999;121.
14. Kawa S., Nikaido T., Aoki Y., Zhai Y., Kumagai T., Furihata K., Fujii S., Kiyosawa K. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br. J. Cancer. 76:1997;884.
15. Tolis C., Peters G.J., Ferreira C.G., Pinedo H.M., Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur. J. Cancer. 35:1999;796.
16. Achenbach T.V., Muller R., Slater E.P. Synergistic antitumor effect of chemotherapy and antisense-mediated ablation of the cell cycle inhibitor p27KIP-1. Clin. Cancer Res. 6:2000;3006.
17. Schreiber M., Muller W.J., Singh G., Graham F.L. Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene. 18:1999;1663.
18. Joshi U.S., Dergham S.T., Chen Y.Q., Dugan M.C., Crissman J.D., Vaitkevicius V.K., Sarkar F.H. Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus. Pancreas. 16:1998;107.
19. Cusack J.C. Jr, Liu R., Houston M., Abendroth K., Elliott P.J., Adams J., Baldwin A.S. Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341 implications for systemic nuclear factor-κB inhibition . Cancer Res. 61:2001;3535.
20. Wagenknecht B., Hermisson M., Eitel K., Weller M. Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. Cell Physiol. Biochem. 9:1999;117.
21. Shah S.A., Potter M.W., McDade T.P., Ricciardi R., Perugini R.A., Elliott P.J., Adams J., Callery M.P. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem. 82:2001;110.
22. Bold R.J., Virudachalam S., McConkey D.J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 100:2001;11.
23. Perez E.A., Buckwalter C.A. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines. Cancer Chemother. Pharmacol. 41:1998;448.
24. Zoli W., Ricotti L., Barzanti F., Dal Susino M., Frassineti G.L., Milandri C., Casadei Giunchi D., Amadori D. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int. J. Cancer. 80:1999;413.
25. Tesei A., Ricotti L., Paola F.D., Amadori D., Frassineti G.L., Zoli W. In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin. Cancer Res. 8:2002;233.
26. Nawrocki S.T., Bruns C.J., Harbison M.T., Bold R.J., Gotsch B.J., Abbruzzese J.L., Elliott P., Adams J., McConkey D.J. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic cancer tumor xenografts. Mol. Cancer Ther. 1:2002;1243.
27. Teicher B.A., Ara G., Herbst R., Palombella V.J., Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5:1999;26385.
28. Adams J., Behnke M., Chen S., Cruickshank A.A., Dick L.R., Grenier L., Klunder M.M., Ma Y.T., Plamondon L., Stein R.L. Potent and selective inhibitors of the proteasome dipeptidyl boronic acids . Bioorg. Med. Chem. Lett. 8:1998;333.
29. Bold R.J., Chandra J., McConkey D.J. Gemcitabine-induced apoptotic cell death of human pancreatic carcinoma is determined by BCL-2 content. Ann. Surg. Oncol. 6:1999;2795.
30. Grenman R., Burk D., Virolainen E., Buick R.N., Church J., Schwartz D.R., Carey T.E. Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int. J. Cancer. 44:1989;131.
31. Bouvet M., Bold R.J., Lee J., Evans D.B., Abbruzzese J.L., Chiao P.J., McConkey D.J., Chandra J., Chada S., Fang B., Roth J.A. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann. Surg. Oncol. 5:1998;681.
32. Zoli W., Ricotti L., Tesei A., Barzanti F., Amadori D. In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit. Rev. Oncol. Hematol. 37:2001;69.
33. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D., Maas J., Pien C.S., Prakash S., Elliott P.J. Proteasome inhibitors a novel class of potent and effective antitumor agents . Cancer Res. 59:1999;2615.
34. Adams J., Palombella V.J., Elliott P.J. Proteasome inhibition a new strategy in cancer treatment . Invest. New Drugs. 18:2000;109.
35. Biswas D.K., Martin K.J., McAlister C., Cruz A.P., Graner E., Dai S.C., Pardee A.B. Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappaB activation. Cancer Res. 63:2003;290.
36. Arlt A., Vorndamm J., Breitenbroich M., Folsch U.R., Kalthoff H., Schmidt W.E., Schafer H. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene. 20:2001;859.
37. Steiner T., Junker U., Henzgen B., Nuske K., Durum S.K., Schubert J. Interferon-alpha suppresses the antiapoptotic effect of NF-kB and sensitizes renal cell carcinoma cells in vitro to chemotherapeutic drugs. Eur. Urol. 39:2001;478.
38. Bandala E., Espinosa M., Maldonado V. Melendez-Zajgla J. Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer exposed to gemcitabine. Biochem. Pharmacol. 62:2001;13.
39. rd, Mackay S. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery. 130:2001;363.
40. Jones D.R., Broad R.M., Madrid L.V., Baldwin A.S. Jr, Mayo M.W. Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann. Thorac. Surg. 70:2000;930.
41. Tabata M., Ganapathi R.N.F. -kappa B activation in topoisomerase I inhibitor-induced apoptotic cell death in human non-small cell lung cancer. Ann. NY Acad. Sci. 922:2000;343.
42. Bottero V., Busuttil V., Loubat A., Magne N., Fischel J.L., Milano G., Peyron J.F. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin a brake to apoptosis in HeLa human carcinoma cells . Cancer Res. 61:2001;7785.
43. Sunwoo J.B., Chen Z., Dong G., Yeh N., Crowl Bancroft C., Sausville E., Adams J., Elliott P., Van Waes C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7:2001;1419.
44. Adjei A.A., Erlichman C., Davis J.N., Cutler D.L., Sloan J.A., Marks R.S., Hanson L.J., Svingen P.A., Atherton P., Bishop W.R., Kirschmeier P., Kaufmann S.H.A. Phase I trial of the farnesyl transferase inhibitor SCH66336 evidence for biological and clinical activity . Cancer Res. 60:2000;1871.